Heart failure
Jul 15, 2025
Nanoscope’s MCO-010 Begins FDA Rolling Submission for Retinitis Pigmentosa; Bayer’s KERENDIA Approved by FDA for Heart Failure With Preserved Ejection Fraction; Klotho Neurosciences’ KLTO-202 Receives FDA Orphan Drug Designation for ALS; Trethera’s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer; Adcentrx’s ADRX-0405 Awarded FDA Orphan Drug Designation for Gastric Cancer
Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa Nanoscope Therapeutics has initiated a rolling submission of its Biologics License Application (BLA) to the FDA for MCO-010, a first-in-class, gene-agnostic optogenetic therapy targeting severe vision loss due to retinitis p...
Read More...
Jun 18, 2025
Exploring Life-Saving Heart Devices: Innovations Transforming Cardiac Care
Heart disease continues to be a major global health concern, impacting countless lives and placing a significant burden on healthcare systems worldwide. According to the World Health Organization, cardiovascular diseases are responsible for approximately 17.9 million deaths each year, accounting for nearly one-thir...
Read More...
Apr 21, 2025
ACC.25 Highlights: Groundbreaking Advances in Cardiovascular Medicine and Emerging Therapeutics
The American College of Cardiology’s 74th Annual Scientific Session and Expo (ACC.25) convened from March 29 to March 31, 2025, in Chicago, Illinois, serving as a pivotal platform for the latest advancements in cardiovascular medicine. The conference attracted over 280 companies and organizations, showcasing innova...
Read More...
Jan 17, 2025
Everything You Need to Know About Acute Kidney Injury
Acute Kidney Injury (AKI) is a significant medical condition that affects millions of individuals worldwide each year. It is a rapidly progressive condition that requires timely diagnosis and treatment to prevent severe complications or long-term consequences. AKI is particularly prevalent in hospitalized patients,...
Read More...
Apr 23, 2024
Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...
Read More...
Aug 24, 2023
Smith+Nephew’s Hip Arthroplasty System; Mammotome Launched the HydroMARK Plus Breast Biopsy Site Marker; FDA Clearance for Pioneering MARS System; CE Marks for NGS-based Test Kits; BaroPace Updated on Non-Pharmacologic Hypertension and Heart Failure Treatment Trial; Quanta Completed Enrollment in Home Run Study
Smith+Nephew Launched Hip Arthroplasty System in India On August 17, 2023, The London-based orthopedic device maker Smith+Nephew announced the launch of its OR3O dual mobility system for use in primary and revision hip arthroplasty in India. The dual mobility implants have a smaller-diameter femoral hea...
Read More...
Jun 06, 2023
Daiichi Sankyo’s Intravenous Iron Replacement Therapy; ANeuroTech’s Adjunctive Anti-depression Drug, ANT-01; Kyverna Therapeutics’s KYV-101 in Lupus Nephritis; Servier Presents Data from Phase 3 INDIGO Trial of Vorasidenib; FDA Approves Pfizer’s ABRYSVO
FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults Pfizer Inc. announced that the FDA has authorized ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory...
Read More...
Jun 05, 2023
LEXICON’s INPEFA: Entry of Another Drug for Heart Failure Treatment
Heart failure is a global pandemic that affects at least 26 million people globally and is becoming more common. Heart failure health expenditures are substantial and will rise considerably as the population ages. Despite significant advancements in medicines and prevention, mortality and morbidity remain high, and...
Read More...
May 30, 2023
FDA Approves Lexicon’s INPEFA (Sotagliflozin); PTC Therapeutics’s Vatiquinone MOVE-FA Registration-Directed Trial; EU Approval to Novartis’s Sickle Cell Disease Drug; EMA Approves Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC; FDA Grants Priority Review to Fruquintinib for mCRC; FDA Orphan Drug Designation to Vega Therapeutics’s VGA039
Lexicon Announces FDA Approval of INPEFA (Sotagliflozin) For Treatment of Heart Failure Lexicon Pharmaceuticals, Inc. announced that the FDA has approved INPEFATM (sotagliflozin), a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure vis...
Read More...
Jun 23, 2022
CE Mark to Ibex’s Gastric Cancer Detection System; Senseonics’s Eversense E3 Continuous Glucose Monitoring System; NEUSPERA’s NUVELLA SYSTEM; Conformal Medical Initiates CONFORM Pivotal Trial; Meridian Launches New qPCR Master Mixes for Stool Samples; Sentinel Diagnostics Launches SENTiFIT 800
Conformal Medical Announces Launch of CONFORM Pivotal Trial On June 17, 2022, Conformal Medical Inc, is a medical device company manufacturing devices to avoid strokes in patients with non-valvular atrial fibrillation and developing next-generation LAAO technology. Its exclusive technology is intended to make le...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
